Molecular Typing of Canine Parvovirus from Sulaimani, Iraq and Phylogenetic Analysis Using Partial Vp2 Gene by Sheikh, M. O. Baba et al.
  
Bulgarian Journal of Veterinary Medicine, 2017, 20, No 3, 225–235 
ISSN 1311-1477; DOI: 10.15547/bjvm.1032
 
Original article 
 
MOLECULAR TYPING OF CANINE PARVOVIRUS FROM 
SULAIMANI, IRAQ AND PHYLOGENETIC ANALYSIS  
USING PARTIAL VP2 GENE 
M. O. BABA SHEIKH1,2, P. M. A. RASHID2, A. S. MAROUF2,  
Z. H. RAHEEM2, S. MANJUNATH1 & S. C. JANGA1,3,4 
1School of Informatics and Computing, Indiana University, Purdue University, 
Indianapolis, Indiana, USA; 2Department of Molecular Biology – Veterinary 
Laboratory Venter, Sulaimani Veterinary Directorate, Iraq; 3Center for Computatio-
nal Biology and Bioinformatics, Indiana University School of Medicine, 
Indianapolis, Indiana, USA; 4Department of Medical and Molecular Genetics, 
Indiana University School of Medicine, Indianapolis, Indiana, USA 
Summary 
Baba Sheikh, M. O., P. M. A. Rashid, A. S. Marouf, Z. H. Raheem, S. Manjunath & S. C. 
Janga, 2017.  Molecular typing of canine parvovirus from Sulaimani, Iraq and phylogenetic 
analysis using partial VP2 gene. Bulg. J. Vet. Med., 20, No 3, 225–235. 
 
Canine parvovirus (CPV) remains the most significant viral cause of haemorrhagic enteritis and 
bloody diarrhoea in puppies over the age of 12 weeks. The objective of the present study was to 
detect and genotype CPV-2 by polymerase chain reaction (PCR) and to perform phylogenetic analysis 
using partial VP2 gene sequences. We analysed eight faecal samples of unvaccinated dogs with signs 
of vomiting and bloody diarrhoea during the period from December 2013 to May 2014 in different 
locations in Sulaimani, Kurdistan, Iraq. After PCR detection, we found that all viral sequences in our 
study were CPV-2b variants, which differed genetically by 0.8% to 3.6% from five commercially 
available vaccines. Alignment between eight nucleotides of field virus sequences showed 95% to 
99.5% similarity.  The phylogenetic analysis for the 8 field sequences formed two distinct clusters 
with two sequences belonging to strains from China and Thailand and the other six – with a strain 
from Egypt. Molecular characterisation and CPV typing are crucial in epidemiological studies for 
future prevention and control of the disease.  
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INTRODUCTION 
Canine parvovirus (CPV-2) causes a 
highly contagious and often fatal disease 
in dogs (Nandi et al., 2009; Yang et al., 
2009). Symptoms in puppies over two 
month include haemorrhagic enteritis, 
bloody diarrhaea, vomiting, leukopaenia, 
nausea and myocarditis; the disease re-
sults in high morbidity (100%) and mor-
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tality (Yilmaz et al., 2005; Yang et al., 
2009). Canine parvovirus (CPV) was first 
identified in 1978 in the United States 
(Martella et al., 2004; Nandi et al., 2009;) 
and was designated CPV type 2 (CPV-2) 
to differentiate it from a previously recog-
nised parvovirus of dogs known as minute 
virus of canines (MVC) which is not re-
lated antigenically to CPV-2 (Zhang et al., 
2010). In the 1980s, two antigenic vari-
ants of CPV-2, distinguished by using 
monoclonal antibodies, emerged simulta-
neously, and they were termed CPV-2a 
and CPV-2b (Parker et al., 2001). These 
two antigenic variants, CPV-2a and CPV-
2b are now distributed worldwide (Decaro 
et al., 2007). A third CPV variant, first 
named Glu-426 mutant and subsequently 
renamed CPV-2c, was detected in Italy in 
2000 (Buonavoglia et al., 2001). Accord-
ing to epidemiological surveillance, CPV-
2a, CPV-2b and CPV-2c are prevalent at 
different proportions in many countries 
(Kumar et al., 2010; Firoozjaii et al., 
2011), and their relative frequencies vary 
according to the geographic region ana-
lysed and the time of sample collection. 
Recent epidemiological studies have indi-
cated that CPV-2a is the predominant 
strain in Australia, India, and Korea 
(Pérez et al., 2012). In China, Iran, Tai-
wan, and Japan CPV-2b is the most preva-
lent (Mohyedini et al., 2013; Singh et al., 
2015). CPV-2b and CPV-2c are both fre-
quently identified in the United States 
with CPV-2c being the more prevalent 
variant in Italy, Argentina, and Uruguay 
(Pérez et al., 2012).  
CPV-2 is a small, non-enveloped, sin-
gle-stranded DNA virus (5.2 kb) which is 
a member of the genus Parvovirus of the 
family Parvoviridae (Guo et al., 2013; 
Zhong et al., 2014). The genome encodes 
two nonstructural proteins (NS 1 and NS 
2) and two structural proteins (VP1 and 
VP2). The VP2 protein is a major capsid 
protein and plays a role in viral patho-
genicity and the host immune response 
(Chinchkar et al. 2006; Zhong et al., 
2014). In the present study, we investi-
gated the genetic composition of the VP2 
region of the CPV-2 genome using mo-
lecular diagnostics (PCR) to understand 
the evolution of field viruses and their 
relation to specific viral vaccines.  
Despite the widespread prevalence of 
canine parvovirus disease CPV-2 in the 
Iraq canine population, molecular diagno-
sis of CPV variants and investigation of 
the trends of its genetic changes is a new 
effort. 
Antigenic detection of CPV in Iraq 
occurred for the first time in 2010 (Al-
Bayati et al., 2010) and its molecular de-
tection took place in 2012 (Ahmed et al., 
2012). Molecular characterisation of Iraqi 
isolates of CPV-2 has not been attempted 
so far. Comprehensive molecular studies 
in this area are required to increase 
knowledge of the genetic diversity of 
CPV-2 in this region to implement an ef-
fective vaccination protocol. The purpose 
of the current study was to characterise 
CPV-2 isolate genetically in Sulaima-
ni/Iraq and to compare their sequences 
with the global CPV-2 and with five 
common commercially available vaccine 
strains. 
MATERIALS AND METHODS 
Samples preparation 
The samples investigated consisted of 
rectal swabs from eight unvaccinated 
dogs, six of which were from the German 
shepherd breed, aged 6–18 months. The 
other two dogs were of the local Hawshar 
breed, 15 months of age. All of the dogs 
had clinical signs of vomiting, bloody 
diarrhoea and dehydration. Samples were 
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collected from the Bakrajo Veterinary 
Department in Sulaimani province be-
tween December 2013 and May 2014. 
Samples were labelled appropriately and 
transported to the Sulaimani veterinary 
laboratory in cold packs within hours of 
sample collection. 
DNA extraction 
The rectal swab samples were vortexed in 
phosphate buffered saline (1 mL 0.1 M 
PBS of pH 7), then genomic DNA was 
extracted from faecal specimens using a 
DNA extraction kit (Genaid Co, Korea) 
according to the manufacturer's instruc-
tions. 
Oligonucleotide primers  
In the current study, we used three sets of 
primers, selected from different regions of 
the VP2 gene that encodes for the virus 
capsid protein. The first primer pair (p1 & 
p2) was designed for specific-group detec-
tion of CPV-2 (Sharma et al., 2012), the 
second set of primers (CPV-2ab-F & 
CPV-2ab-R) was specific for detection of 
CPV type-2a and 2b (Buonavoglia et al., 
2001; Kumar et al., 2011) and the final 
primer pair (CPV-2b-F & CPV-2b-R) is 
specific for detecting CPV type 2b (Nandi 
et al., 2010). For detailed information of 
on primer sets see Table 1. All of the set 
primers are synthesised by Bioneer & 
Macrogen Co. (Korea). 
Amplification of DNA extracts 
Polymerase chain reaction (PCR) is con-
sidered as the most precise diagnostic 
technique with a high degree of sensitivity 
and specificity in detecting CPV from 
faecal samples (Decaro et al., 2005). Par-
tial sequence of VP2 gene was amplified 
by using Accu-Power PCR Premix (Bion-
eer, Korea). The reactions were carried 
out in 0.2 mL PCR tube based on the fol-
lowing specifications: 5 μL DNA, 1 μL 
forward (10 pmol), 1 μL reverse primers 
(10 pmol), and 13 μL ultra-pure water to 
make up final volume of 20 μL. The con-
ventional PCR machine was programmed 
as followed: initial denaturation at 95 °C 
for 5 min followed by 30 cycles of 95 °C 
for 1 min; annealing at 50 °C for 30 s, and 
extension at 72 °C for 1 min (the exten-
sion time for CPV-F & CPV-R primers 
was 2 min), and a final extension at 72 °C 
for 10 min. Ten μL of the amplified PCR 
products was run on 1% agarose gel and 
stained with ethidium bromide in  Tris-
acetate-EDTA (TAE) buffer (1×). The 
PCR product was run via gel electropho-
resis and visualised under UV trans illu-
minator (UVETIC, UK). 
Phylogenetic analysis 
For the phylogenetic analysis, 31 canine 
parvovirus VP2 sequences from various 
parts of the world and five commercial 
vaccine strains were retrieved from the 
Table 1. Primers used in the study 
Primers name Sequence primers (5’→3’) Position Product size 
P1 –F  
P2 –R 
CAAATAGAGCATTGGGCTTACC 
CAATCTCCTTCT-GGATATCTTC 
 400 bp 
CPV-2ab-F 
CPV-2ab-R 
GAAGAGTGGTTGTAAATAATT 
CCTATATAACCAAAGTTAGTAC 
3025–3045 
3685–3706 
681 bp 
CPV-2b-F 
CPV-2b-R 
CTTTAACCTTCCTGTAACAG 
CAGTTAAATTGGTTATCTAC 
4043–4062 
4449–4470 
427 bp 
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GenBank and used. The sequence homo-
logy and multiple sequence alignment at 
the nucleotide and the amino acid level 
were performed by CLUSTALW program 
(Thompson et al., 1994). The evolutiona-
ry partial VP2 sequences were inferred by 
using the Neigbour-joining phylogenetic 
tree method using a Kimura 2-parameter 
model with MEGA6 software (Tamura et 
al., 2013). The topological accuracy of 
the tree was estimated by the bootstrap 
method, with 1000 replicates.  
RESULTS  
CPV-2 identification and genotyping  
Eight samples were screened by PCR as-
say using P1 & P2 primer pairs and ex-
pected size 400 bp (Fig. 1). All samples 
were found to be positive using the CPV-
2ab primer pair and expected size 681 bp 
(Fig. 2). Also, all samples tested positive 
for CPV DNA by PCR using CPV-2b 
specific primers and expected size 427 bp 
(Fig. 3), indicating that the field sequen-
ces were 2b variant.  
Sequencing of the PCR products con-
firmed the results (Macrogen Sequencing 
Service, Korea). The nucleotide sequen-
ces of CPV-2b isolates generated in the 
study are available from GenBank with 
accession No. KF996497, KM047042, 
KM047043, KM047044, KM047045, 
KM047046, KM047047, KM047048, 
KP313628, KP313629, KP313630, and 
KP335051). 
Sequence and phylogenetic analysis 
The eight CPV-2 sequences identified in 
this study, 20 published full sequences of 
the CPV VP2 gene and five commercial 
VP2 sequences from CPV-2 vaccines 
were included in the analysis. The CPV-2 
sequences originated from different conti-
nents including Asia, Europe, Africa and 
USA country. The VP2 sequences formed 
five distinct clusters (C1–C5). Six virus 
sequences from this study clustered within 
the C5 branch, together with the CPV-2 
from Egypt (KM21294). Two remaining 
virus sequences clustered within the C4 
branch  with CPV-2 sequences from Thai-
land, Taiwan, and China (accession No. 
JX048607, GQ379042, and KF785794 
respectively) (Fig. 4). 
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Fig. 1. Agarose gel showing amplification of 
the partial VP-2 gene (400 bp) using primer 
set P1-F and P2-R.  Lane M: DNA marker 100 
bp, lanes 1–5: (400 bp) PCR product of Sulai-
mani sequences virus; lane 6: negative. 
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Fig. 2. Agarose gel showing amplification of 
the partial VP-2 gene (681 bp) using primer 
set CVP-2ab-F and CPV-2ab-R. Lane M: 
DNA marker 100 bp, lanes 1–4: (681 bp) PCR 
product of Sulaimani sequences virus, lane 5: 
negative. 
Similarities and divergences of the 
eight CPV-2 sequences from the Sulaima- 
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Fig. 3. Agarose gel showing amplification of the partial VP-2 gene (427 bp) using primer set CVP-2b-F 
and CPV-2b-R. Lane M = DNA marker 100 bp, Lane 1-8:  (427 bp) PCR product of Sulaimani 
sequences virus. 
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Fig. 4. Neighbour joining tree (Mega-6-version) constructed using canine parvovirus sequences under 
study and the reference sequences of different countries and five commercial vaccinal strains. 
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CPV/Sulaimani/4 --------------------------------------DDTHAQIVTPWSLVDANAWGVW 22  
CPV/Sulaimani/7 --------------------------------------DDTHAQIVTPWSLVDANAWGVW 22  
CPV/Sulaimani/1 --------------------------------------DDTHAQIVTPWSLVDANAWGVW 22  
CPV/Sulaimani/5 --------------------------------------DDTHAQIVTPWSLVDANAWGVW 22  
CPV/Sulaimani/2 --------------------------------------DDTHAQIVTPWSLVDANAWGVW 22  
CPV/Sulaimani/3 --------------------------------------DDTHAQIVTPWSLVDANAWGVW 22  
CPV/Sulaimani/6 --------------------------------------DDTHAQIVTPWSLVDANAWGVW 22  
CPV/Sulaimani/8 --------------------------------------DDTHAQIVTPWSLVDANAWGVW 22  
Duramune/DAPPI  ITANSSRLVHLNMPESENYRRVVVNNLDKTAVNGNMALDDTHAQIVTPWSLVDANAWGVW 60  
Pfizer/vaccine  ITANSSRLVHLNMPESENYRRVVVNNMDKTAVNGNMALDDIHAQIVTPWSLVDANAWGVW 60  
vaccine-Korea   ITANSSRLVHLNMPESENYRRVVVNNMDKTAVNGNMALDDIHAQIVTPWSLVDANAWGVW 60 
Intervet/vacc   ITANSSRLVHLNMPESENYRRVVVNNMDKTAVNGNMALDDIHAQIVTPWSLVDANAWGVW 60  
Merial/vaccine  ITANSSRLVHLNMPESENYRRVVVNNMDKTAVNGNMALDDIHAQIVTPWSLVDANAWGVW 60  
                                                      ** *******************  
                                                   95  
CPV/Sulaimani/4 FNPGDWQLIVNTMSELHLVSFEQEIFNVVLKTVSESATQPPTKVYNNDLTASLMVALDSN 82  
CPV/Sulaimani/7 FNPGDWQLIVNTMSELHLVSFEQEIFNVVLKTVSESATQPPTKVYNNDLTASLMVALDSN 82  
CPV/Sulaimani/1 FNPGDWQLIVNTMSELHLVSFEQEIFNVVLKTVSESATQPPTKVYNNDLTASLMVALDSN 82  
CPV/Sulaimani/5 FNPGDWQLIVNTMSELHLVSFEQEIFNVVLKTVSESATQPPTKVYNNDLTASLMVALDSN 82  
CPV/Sulaimani/2 FNPGDWQLIVNTMSELHLVSFEQEIFNVVLKTVSEFVIQPPTKVYNNDLTASLMVALDSN 82  
CPV/Sulaimani/3 FNPGDWQLIVNTMSELHLVSFEQEIFNVVLKTVSESATQPPTKVYNNDLTASLMVALDSN 82  
CPV/Sulaimani/6 FNPGDWQLIVNTMSELHLVSFEQEIFNVVLKTVSESATQPPTKVYNNDLTASLMVALDSN 82  
CPV/Sulaimani/8 FNPGDWQLIVNTMSELHLVSFEQEIFNVVLKTVSESATQPPTKVYNNDLTASLMVALDSN 82  
Duramune/DAPPI  FNPGDWQLIVNTMSELHLVSFEQEIFNVVLKTVSESATQPPTKVYNNDLTASLMVALDSN 120  
Pfizer/vaccine  FNPGDWQLIVNTMSELHLVSFEQEIFNVVLKTVSESATQPPTKVYNNDLTASLMVALDSN 120  
Vaccine-Korea   FNPGDWQLIVNTMSELHLVSFEQEIFNVVLKTVSESATQPPTKVYNNDLTASLMVALDSN 120 
Intervet/vacc   FNPGDWQLIVNTMSELHLVSFEQEIFNVVLKTVSESATQPPTKVYNNDLTASLMVALDSN 120  
Merial/vaccine  FNPGDWQLIVNTMSELHLVSFEQEIFNVVLKTVSESATQPPTKVYNNDLTASLMVALDSN 120  
                *********************************** . **********************  
                                
CPV/Sulaimani/4 NTMPFTPAAMRSETLGFYPWKPTIPTPWRYYFQWDRTLIPSHTGTSGTPTNIYHGTDPDD 142  
CPV/Sulaimani/7 NTMPFTPAAMRSETLGFYPWKPTIPTPWRYYFQWDRTLIPSHTGTSGTPTNIYHGTDPDD 142  
CPV/Sulaimani/1 NTMPFTPAAMRSETLGFYPWKPTIPTPWRYYFQWDRTLIPSHTGTSGTPTNIYHGTDPDD 142  
CPV/Sulaimani/5 NTMPFTPAAMRSETLGFSPGKPTIPTPWRYYFQWDRTLIPSHTGTSGTPTNIYHGTDPDD 142  
CPV/Sulaimani/2 NTMPFTPAAMRSETLGFYPWKPTIPTPWRYYFQWDRTLIPSHTGTSGTPTNIYHGTDPDD 142  
CPV/Sulaimani/3 NTMPFTPAAMRSETLGFYPWKPTIPTPWRYYFQWDRTLIPSHTGTSGTPTNIYHGTDPDD 142  
CPV/Sulaimani/6 NTMPFTPAAMRSETLGFYPWKPTIPTPWRYYFQWDRTLIPSHTGTSGTPTNIYHGTDPDD 142  
CPV/Sulaimani/8 NTMPFTPAAMRSETLGFYPWKPTIPTPWRYYFQWDRTLIPSHTGTSGTPTNIYHGTDPDD 142  
Duramune/DAPPI  NTMPFTPAAMRSETLGFYPWKPTIPTPWRYYFQWDRTLIPSHTGTSGTPTNIYHGTDPDD 180  
Pfizer/vaccine  NTMPFTPAAMRSETLGFYPWKPTIPTPWRYYFQWDRTLKPSHTGTSGTPTNIYHGTDPDD 180 
vaccine-Korea   NTMPFTPAAMRSETLGFYPWKPTIPTPWRYYFQWDRTLVPSHTGTSGTPTNIYHGTDPDD 180  
Intervet/vacc   NTMPFTPAAMRSETLGFYPWKPTIPTPWRYYFQWDRTLVPSHTGTSGTPTNIYHGTDPDD 180  
Merial/vaccine  NTMPFTPAAMRSETLGFYPWKPTIPTPWRYYFQWDRTLIPSHTGTSGTPTNIYHGTDPDD 180  
                ***************** * ****************** *********************  
                                180         193      222  226  
CPV/Sulaimani/4 VQFYTIENSVPVHLLRTGDEFATGTFYFDCKPCRLTHTWQTNRALGLPPFLNSLPQAEGGT 202  
CPV/Sulaimani/7 VQFYTIENSVPVHLLRTGDEFATGTFYFDCKPCRLTHTWQTNRALGLPPFLNSLPQAEGGT 202  
CPV/Sulaimani/1 VQFYTIENSVPVHLLRTGDEFATGTFYFDCKPCRLTHTWQTNRALGLPPFLNSLPQAEGGT 202  
CPV/Sulaimani/5 VQFYTIENSVPVHLLRTGDEFATGTFYFDCKPCRLTHTWQTNRALGLPPFLNSLPQAEGGT 202  
CPV/Sulaimani/2 VQFYTIENSVPVHLLRTGDEFATGTFYFDCKPCRLTHTWQTNRALGLPPFLNSLPQAEGGT 202  
CPV/Sulaimani/3 VQFYTIENSVPVHLLRTGDEFATGTFYFDCKPCRLTHTWQTNRALGLPPFLNSLPQAEGGT 202  
CPV/Sulaimani/6 VQFYTIENSVPVHLLRTGDEFATGTFYFDCKPCRLTHTWRTNRALGLPPFLNSLPQAEGGT 202  
CPV/Sulaimani/8 VQFYTIENSVPVHLLRTSDEFATGTFYFDCSPCRLTHTWWANRSV--------------- 187  
Duramune/DAPPI  VQFYTIENSVPVHLLRTGDEFATGTFFFDCKPCRLTHTWQTNRALGLPPFLNSLPQAEGGT 224  
Pfizer/vaccine  VQFYTIENSVPVHLLRTGDEFATGTFFFDVKPCRLTHTWQTNRALGLPPFLNSLPQSEGAT 224  
vaccine-Korea   VQFYTIENSVPVHLLRTGDEFATGTFFFDCKPCRLTHTWQTNRALGLPPFLNSLPQSEGAT 224 
Intervet/vacc   VQFYTIENSVPVHLLRTGDEFATGTFFFDCKPCRLTHTWQTNRALGLPPFLNSLPQSEGAT 224 
Merial/vaccine  VQFYTIENSVPVHLLRTGDEFATGTFFFDCRPCRLTHTWQTNRALGLPPFLNSLPQSEGAT 224 
                           *****************.********:** ******** :**::* 
Fig. 5. Eight fields isolate sequences alignment with five commercial vaccine references. 
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ni and other CPV-2 sequences were com-
pared with 12 CPV-2 sequences from 
seven different countries and five com-
mercial vaccines (Table 2); the eight virus 
sequences from the Sulaimani showed 
nucleotide identities of 95%–99.5% and 
divergences of 5%–0.5% between them. 
The eight CPV/Sulaimani sequences were 
most similar to the CPV-2 sequences from 
Egypt and China respectively, with identi-
ties of 97.1%–99.8%. Also, when the eight 
CPV/Sulaimani sequences were compared 
with five vaccine strains the highest simi-
larity was exhibited with the Duramune 
DAPPI+LC-2b (FJ222822) vaccinal strain:  
97.1%– 9.2% and divergence 2.9%–0.8%.  
The multiple sequence alignment of 
the partial amino acid sequence of VP2 
gene from Sulaimani and from five CPV-2 
vaccines showed that the vaccine strain 
Duramune DAPPI+LC-2b (FJ222822) 
was most similar to the Iraqi field viruses. 
The sequence alignment showed that the 
amino acid in position 267 in eight Su-
laimani field sequences differed from 
Duramune DAPPI+LC-2b vaccine while 
amino acid positions 101, 219 and 267 
differed from other four CPV-2 vaccinal 
strains (Pzifer, Intervet, Merial and Korea 
vaccines) (Fig. 5). These differences be-
tween vaccines and field isolates may lead 
to increased pathogenicity of the virus and 
insufficient immune response induced by 
the vaccines in hosts. 
DISCUSSION 
Canine parvovirus infection is distributed 
worldwide and has emerged as a signifi-
cantly fatal disease in puppies. Moreover, 
genetic variation among CPV-2 isolates 
can be used to classify further the viruses 
into four genotypes (2, 2a, 2b, and 2c) that 
differ in their amino acid sequence and 
VP2 gene phylogenetic relationships 
(Martella et al., 2006; Parthiban et al., 
2010;). Our results indicate that CPV-2b 
is currently the only virus circulating in 
Sulaimani/Iraq. VP2 encodes a viral cap-
sid protein that is the major structural pro-
tein of CPV-2 and is involved in the host 
immune response. Therefore, a small 
number of mutations may result in in-
creased pathogenicity (Lin et al., 2014). 
CPV possesses a high genetic substitution 
rate, similar to that observed for RNA 
viruses, which is responsible for continu-
ous antigenic evolution and rapid dis-
placement of old types by new antigenic 
variants (Decaro et al., 2007a,b). As 
shown on Fig. 5, where CPV/Sulaimani/1 
was compared with other seven field virus 
sequences showing sporadic mutation 
occurring during five months of samples 
collection, these results indicate that CPV-
2 has unstable DNA genome. Amino acid 
comparisons among the eight isolates and 
the five reference vaccines revealed that 
CPV/Sulaimani/2 and CPV/Sulaimani/8 
isolates exhibited some non-synonymous 
mutations, in CPV/Sulaimani/2 at the po-
sition 95, 96 and 97 leading to variants  F, 
V and I instead of S, A and T respec-
tively. We also found that in CPV/Sulai-
mani/8, the positions 180, 193, 222, 223 
and 226 were altered to S, S, W, A and S 
instead of G, K, Q, T and A respectively 
(Fig 5). Even though CPV-2 appeared in 
Iraq around 2010 (Al-Bayati et al., 2010), 
there is no data about CPV-2 sequences 
existing in the country in previous years to 
allow comparative analysis of the evolu-
tion of CPV-2 variants over time. Accord-
ing to one study conducted in Baghdad, 
CPV-2b was the predominant strain in 
parvovirus infected dogs (Ahmed et al., 
2012) which is compatible with our results 
(hundred percentage variant CPV-2b). 
Phylogenetic tree analysis showed that 
the CPV-2 Sulaimani sequences virus 
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separated and formed two distinct clus-
ters, one cluster containing a sequence 
from Egypt and another cluster containing 
sequences from China and Taiwan (Fig. 4) 
indicating that the field virus sequences 
have at least two sources of CPV-2 infec-
tion.  
Comparison of the eight field CPV-2 
sequences (Table 2) and alignment (Fig. 
5)  showed high similarity (97.1%–99.2%) 
and lower amino acid substitutions with 
the Duramune DAPPI+LC-2b vaccine 
strain than with the other four CPV-2 vac-
cinal strains. According to the results of 
the present study, the Duramune DAPPI 
+LC-2b vaccinal strain appeared to be the 
best choice for vaccination of dogs from 
Sulaimani, Iraq.  
It is significant to ensure scheduled 
vaccination before buying a puppy or dog. 
Whether the CPV-2 epidemiology in Su-
laimani and another city is related to dif-
ferent canine vaccination protocols or 
trade practices should be evaluated care-
fully in the future.  
Another important point regarding dog 
vaccinations is attention to maternal anti-
body titre. In practice, immunisation 
against CPV infection is usually based on 
repeated vaccination over a period of 6 to 
18 weeks of age, without considering the 
maternal antibody titre (Nandi et al., 
2009). Haemagglutination inhibition and 
ELISA are the most useful tests to assess 
the antibody level before vaccination 
(Waner et al., 2006).  
However, constant epidemiological 
supervision and sequence analysis of the 
CPV types will help clarify whether this 
mutant has become permanently estab-
lished in the dog population and whether 
it is also spreading in other parts of the 
world, thus providing insights into the 
mechanisms driving the evolution of 
CPV-2. Furthermore, it is important to 
monitor continually the emergence of new 
type of CPV-2 in the dog population in 
Iraq.  
CONCLUSION 
The analysis of VP2 sequence revealed 
that CPV type-2b is currently the most 
prevalent strain circulating in Sulaimani 
province, Iraq. Based on the current study, 
the Duramune DAPPI+LC-2b vaccine 
strain is the best choice for vaccinating 
puppies in this area. Necessary precau-
tions should be taken to control the CPV-
2 in dogs by integrating the indigenous 
strain of CPV in the preparation of the 
vaccine. 
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